A prospective costing study of delivering childhood respiratory syncytial virus (RSV) interventions estimated that the cost of delivering the maternal vaccine was US$1.32 (financial) and US$2.72 (economic), excluding commodity cost. Delivery costs for a long-acting monoclonal antibody were estimated at US$1.23 (financial) and US$2.48 (economic). Cost differences between the two interventions are driven by the anticipated baseline coverage. Health worker training, service delivery and program planning and coordination were major cost drivers. This study presents the prospective cost of new RSV intervention introduction and delivery in low-income and middle-income country settings, which is largely unknown.
Thumbnail image: MargJohnsonVA / Shutterstock.com
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.